Material Impact Partners is a Boston-based venture capital firm founded in 2015 investing in early-stage companies using material science and technology to address societal needs. Its investments span areas including sustainable manufacturing, food and water, healthcare, and other emerging technologies. The Impact Fund is invested in Material Impact Fund II & III.

One example of Material Impact's strategy in action is its investment in Ripple Foods, a Certified B Corporation that harnesses the protein of the yellow pea to create sustainable, plant-based milks, shakes, and half & half. Yellow peas require less water to grow than almonds or dairy and add nitrogen back into the soil. Ripple’s products produce 80% less CO2 than dairy milk, while offering eight times the protein of almond milk and 50% more calcium than 2% dairy milk. Ripple Foods highlights how Material Impact's invests in innovative solutions designed to address environmental challenges while creating better products for consumers.

North Sky Capital is a Minnesota-based private equity firm founded in 2000, specializing in impact secondaries across clean technology and infrastructure. The Impact Fund recently invested $2.0M in North Sky’s Clean Growth Fund VII, which provides diversified exposure to more than 150 underlying companies through a strategy known as “secondaries,” or purchasing existing stakes in private equity funds. Through its investment strategy, North Sky provides exposure to companies addressing environmental and social needs, including clean energy, the circular economy, climate adaptation, healthy living, and financial inclusion.

Past North Sky investments illustrate what this looks like in practice: Ecore is a global leader in transforming rubber waste into performance products and surfaces used across sports and recreation, fitness, healthcare, commercial interiors, and industrial markets. By diverting rubber waste from landfills and giving it new life as high-performance materials, Ecore highlights the Clean Growth circular economy theme.

1315 Capital invests in growth equity healthcare companies developing practical products improving patient care and healthcare delivery. The fund focuses on businesses with proven solutions addressing real-world needs across pharmaceutical products and outsourcing, medtech, and health and wellness. By backing companies with established traction, 1315 Capital supports innovation able to scale and deliver meaningful benefits to patients, providers and healthcare systems while pursuing strong financial returns.

A clear example of 1315 Capital’s impact is its investment in Nu-Tek Biosciences, which uses technology, helping make drug development more sustainable and efficient. Another portfolio company, Biocoat, develops specialized coatings for medical devices that reduce friction and improve performance in tools such as catheters and guidewires. Together, these investments demonstrate how 1315 supports healthcare solutions that enhance safety, efficiency and outcomes in everyday clinical settings.